Table 2.
Important Mediators of GRh2-Induced Anticancer Effects
Key molecule(s) | Activity alteration in response to GRh2 | Pharmacological effects associated | References |
---|---|---|---|
Annexin A2 | DOWN | Apoptosis | [37] |
Akt | DOWN | Apoptosis, Anti-proliferation | [31,45,49,59,72] |
Atg5/7 | UP | Autophagy | [44,45,50,75] |
Bax | UP | Apoptosis | [24,[31], [32], [33],35,36,45,46,52] |
Bak | UP | Apoptosis | [32] |
Bad | UP | Apoptosis | [31,36] |
β-catenin | DOWN | Anti-proliferation | [53,73,75] |
Bcl-2 | DOWN | Apoptosis | [24,30,32,33,35,36,45,46,52] |
Bcl-xL | DOWN | Apoptosis | [32,36] |
Beclin-1 | UP | Autophagy | [45,50] |
Bim | UP | Apoptosis | [31,32] |
Caspases | UP | Apoptosis | [[23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33],39] |
CDKs | DOWN | Anti-proliferation | [26,27,43,52,54,56] |
Cyclins | DOWN | Anti-proliferation | [26,27,45,[52], [53], [54],56] |
E-cadherin | UP | Anti-metastasis and invasion | [50,73] |
E2F | DOWN | Anti-proliferation | [26,54,61] |
EGFR | DOWN | Anti-proliferation | [58,59,64] |
ERK | DOWN | Anti-proliferation | [26,60] |
Fas/FasL | UP | Apoptosis | [23,39] |
HATs | UP | Anti-proliferation | [52] |
HDACs | DOWN | Anti-proliferation | [52,70] |
LC3-Ⅱ/LC3-Ⅰ | UP | Autophagy | [75] |
mTOR | DOWN | Anti-proliferation | [45,49,59] |
MMPs | DOWN | Anti-metastasis and invasion | [53,[70], [71], [72]] |
PI3K | DOWN | Anti-proliferation, Anti-metastasis and invasion | [45,49,72] |
PKCs | UP | Apoptosis | [29] |
Rb | DOWN | Anti-proliferation | [27,54] |
Snail | DOWN | Anti-metastasis and invasion | [50] |
STAT3 | DOWN | Anti-proliferation | [71] |
TGF-β | DOWN | Anti-metastasis and invasion | [50] |
TRAIL/DR4(5) | UP | Apoptosis | [23,27] |
VEGF | DOWN | Anti-angiogenesis | [[67], [68], [69]] |
Vimentin | DOWN | Anti-metastasis and invasion | [50,73] |
Wnt | DOWN | Anti-proliferation | [53,73] |